Philip Vanderlugt
Optometrist · Grand Rapids, MINPI 1942204623
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Alcon at 59.3% of the total. Reporting peaked in 2019 at $8,091 and has fallen 80.2% since, to $1,601 in 2025. Among optometrist clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 125 payments — averaging $92.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$7K
- Biotissue Holdings Inc.$2K
- Coopervision Inc.$746
- AbbVie$738
- Sun Pharmaceutical Industries Inc.$341
- Bausch & Lomb, A Division Of Bausch Health US, LLC$181
- plus $944 from 11 others
What the payments were for
- Speaking & faculty fees$6,91760%
- Travel & lodging$8637%
- Food & beverage$3,70032%
- Entertainment$711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 11 | $6,848 |
| Biotissue Holdings Inc. | 19 | $1,753 |
| Coopervision Inc. | 12 | $746 |
| AbbVie(2 entities) | 27 | $738 |
| Sun Pharmaceutical Industries Inc. | 23 | $341 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $181 |
| Novartis | 4 | $153 |
| Oyster Point Pharma, Inc. | 7 | $144 |
| Shire North American Group Inc | 2 | $141 |
| Aerie Pharmaceuticals, Inc. | 2 | $134 |
| Bausch & Lomb Americas Inc. | 5 | $99 |
| Optos, Inc. | 1 | $71 |
| Astellas Pharma US Inc | 2 | $55 |
| Genentech USA, Inc. | 2 | $48 |
| Dompe US, Inc. | 2 | $38 |
| Harrow Eye, LLC | 1 | $33 |
| Johnson & Johnson Vision Care, Inc. | 2 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES$6,500
- Clariti Contact Lens$417
- Prokera$161
- AmnioGraft$161
- Hydrus Microstent$142
- LUMIGAN$125
- DURYSTA$125
- XIIDRA$123
- ULTRA$123
- BIOTRUE ONE DAY$123
- Rhopressa$120
- Rocklatan$120
- CEQUA$116
- TRAVATAN Z$109
How this compares
$11,551 in reported general payments places this provider in the 95th percentile of 1,523 optometrist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 40 | $17,927 |
| RestasisCyclosporine | 14 | $15,947 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $9,977 |
| Latanoprost | 281 | $5,486 |
| Travoprost | 11 | $3,223 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 41 | $1,426 |
| Timolol Maleate | 104 | $1,360 |
| Doxycycline Hyclate | 31 | $1,129 |
| Prednisolone Acetate | 32 | $899 |
| Fluorometholone | 14 | $847 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 68 | $832 |
| Dorzolamide Hcl | 15 | $367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $738 | $43,85184 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,523 optometrist providers in Michigan.
Other optometrist in Grand Rapids
- Jay CrankGrand Rapids$209K
- Thomas DunningGrand Rapids$7K
- Adam CarlsonGrand Rapids$6K
- Jamie KuzniarBloomfield$473K
- Monica JohnsonbaughGrosse Pointe$393K
- Nicholas BrunsFlint$238K
- Jeffrey VaranelliWarren$204K
- Thomas RothAnn Arbor$98K
- Frances Poma NowinskiBloomfield Twp$91K
- Michael LipsonWalled Lake$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.